VALEANT PHARMS NORTH
PharmaVALEANT PHARMS NORTH is a pharmaceutical company focused on Cardiovascular, Dermatology.
VALEANT PHARMS NORTH's Key Drugs
VALEANT PHARMS NORTH's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
VALEANT PHARMS NORTH's Recent FDA Approvals
New NDA/BLA approvals for VALEANT PHARMS NORTH over the last two years — novel drugs only, excluding generics and label supplements.
VALEANT PHARMS NORTH's Therapeutic Areas
VALEANT PHARMS NORTH's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Dermatology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
VALEANT PHARMS NORTH's Top Competitors
VALEANT PHARMS NORTH's closest competitors by therapeutic-area and drug-target overlap include Baxter, Bayer, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
VALEANT PHARMS NORTH Pipeline Snapshot
Active clinical trials for VALEANT PHARMS NORTH across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1973-01-26
- Latest
- 2025-07-11
- Applications
- 12